Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
InspireMD ( (NSPR) ) just unveiled an update.
InspireMD, Inc. has reported record revenue for Q3 2024, driven by its CGuard Prime carotid stent system, which is moving towards potential U.S. approval. Recent developments include submitting a PMA application to the FDA and receiving IDE approval for pivotal trials. The company anticipates a U.S. commercial launch in early 2025, supported by a new Miami headquarters. Despite increased operating expenses, InspireMD’s strategic advancements position it for growth in the carotid artery disease treatment market.
See more insights into NSPR stock on TipRanks’ Stock Analysis page.
